Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430120 | 0.90 | FLT3 (0.64) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL7065750 | 0.87 | FLT3 (0.64) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL426733 | 0.86 | MEN1 (0.65) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL31705824 | 0.86 | FLT3 (0.64) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL428047 | 0.86 | FLT3 (0.64) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL6395923 | 0.85 | HDAC6 (0.84) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL6866887 | 0.84 | PDGFRB (1.00) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL7066142 | 0.84 | FLT3 (0.69) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL426783 | 0.84 | PDGFRB (0.74) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 | |
| SCHEMBL10176422 | 0.84 | PDGFRB (0.58) | PDGFRBPDGFRAMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | BECKERS THOMAS (DE) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | PDGFRB 2578/4885PDGFRA 2983/4885MEN1 1042/4885 |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | PDGFRB 3105/4885PDGFRA 3726/4885MEN1 2527/4885 |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | PDGFRB 3807/4885PDGFRA 3147/4885MEN1 1405/4885 |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | PDGFRB 3807/4885PDGFRA 3147/4885MEN1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.